Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Bekaii-Saab on Safety Profile of Tucatinib/Trastuzumab in HER2-Amplified mCRC

October 11th 2019

Tanios S. Bekaii-Saab, MD, discusses the safety profile of the combination of tucatinib and trastuzumab in patients with HER2-amplified metastatic colorectal cancer.

Next Steps for Immunoscore in Oncology

October 10th 2019

Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses next steps with Immunoscore in oncology.

ATOMIC Looks at Immunotherapy in Early-Stage dMMR Colon Cancer

October 7th 2019

Investigators are seeking to determine whether immunotherapy that has been effective in metastatic colon cancers with deficient DNA mismatch repair can be applied to earlier-stage disease, specifically, nonmetastatic stage III colon cancer.

Dr. Bekaii-Saab on the Rationale to Evaluate Atezolizumab/Bevacizumab in MSS mCRC

October 5th 2019

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses the rationale to evaluate atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Dr. Manji on Lack of Actionable Targets in Patients with Colorectal Cancer

October 2nd 2019

Gulam A. Manji, MD, PhD, discusses the importance of discovering other actionable targets for patients with colorectal cancer.

Dr. Messersmith on Choosing a Treatment Option in mCRC

September 26th 2019

Wells A. Messersmith, MD, discusses therapeutic options in metastatic colorectal cancer and what factors help determine the most appropriate option.

Dr. Lenz on Updated Results of the CheckMate-142 Trial in mCRC

September 25th 2019

Heinz-Josef Lenz, MD, FACP, discusses updated results from the phase II CheckMate-142 trial in metastatic colorectal cancer.

FDA Approves CRC Screening Test for Younger, At-Risk Individuals

September 23rd 2019

The FDA has expanded the approval of the noninvasive colorectal cancer (CRC) screening test Cologuard to include eligible at-risk individuals ≥45 years.

Top GI Oncologists Share Excitement on 16th Annual ISGIO Conference

September 20th 2019

Gastrointestinal oncology experts highlight what they are most excited for at the upcoming International Society of Gastrointestinal Oncology 16th Annual Gastrointestinal Oncology Conference.

Subset of BRAF non-V600-Mutant mCRC Is Potentially More Sensitive to Anti-EGFR Therapy

September 18th 2019

Patients with metastatic colorectal cancer who harbored BRAF non-V600, RAS-dependent mutations were more likely to respond to anti-EGFR therapy versus those with BRAF non-V600, RAS-independent mutations.

Dr. Manji on Treatment for NTRK Fusion+ CRC

September 18th 2019

Gulam A. Manji, MD, PhD, discusses treatment for patients with colorectal cancer who harbor NTRK fusions.

Key Takeaway 8: MSI-High Status and HER2 Amplification

September 16th 2019

Key Takeaway 7: Role of Immunotherapy in MSI-High MCRC

September 16th 2019

Key Takeaway 6: I/O: Combination vs Monotherapy

September 16th 2019

Key Takeaway 5: Dosing of Multiple Kinase Inhibitors

September 16th 2019

Key Takeaway 4: Right-Sided Tumors: Anti-Angiogenic Treatment

September 16th 2019

Key Takeaway 3: Determining Tumor Mutational Status

September 16th 2019

Key Takeaway 2: Frontline Neoadjuvant Chemotherapy

September 16th 2019

Key Takeaway 1: Adjuvant Therapy Optimal Duration

September 16th 2019

Dr. Lieu Discusses the Focus of Future Research in mCRC

September 12th 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses where future research should focus in metastatic colorectal cancer.